Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy (Q36365590)

13 August 2017

Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy (English)

1 reference

Maryalice Stetler-Stevenson

13 August 2017

8

object named as

Maryalice Stetler-Stevenson

1 reference

13 August 2017

5

Wyndham Wilson

1 reference

13 August 2017

Liuyan Jiang

1

1 reference

13 August 2017

Constance M Yuan

2

1 reference

13 August 2017

Julia Hubacheck

3

1 reference

13 August 2017

John E Janik

4

1 reference

13 August 2017

John C Morris

6

1 reference

13 August 2017

Gregory A Jasper

7

1 reference

13 August 2017

language of work or name

English

0 references

publication date

19 February 2009

1 reference

British Journal of Haematology

13 August 2017

1 reference

13 August 2017

145

1 reference

13 August 2017

2

1 reference

13 August 2017

173-179

1 reference

Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487105

Expression of CD52 in peripheral T-cell lymphoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487105

Alemtuzumab in T-cell lymphoproliferative disorders

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487105

CAMPATH: from concept to clinic

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487105

Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487105

Alemtuzumab in T-cell malignancies

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487105

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487105

High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487105

A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487105

Flow cytometric immunophenotyping of non-Hodgkin's lymphomas and related disorders

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487105

Primary structure of CD52.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487105

Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487105

Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity.

28 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2009.07606.X

Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487105

A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487105

BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487105

Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487105

Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H

22 September 2018

1 reference

12 December 2020

The CAMPATH-1 antigen (CDw52)

1 reference

12 December 2020

Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen

1 reference

12 December 2020

Treatment of T-cell prolymphocytic leukemia with human CD52 antibody

1 reference

12 December 2020

Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H

1 reference

12 December 2020

Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia

1 reference

12 December 2020

Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H)

1 reference

12 December 2020

Quantitative analysis of the expression of glycosylphosphatidylinositol-anchored proteins during the maturation of different hematopoietic cell compartments of normal bone marrow

1 reference

12 December 2020

Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study

1 reference

12 December 2020

10.1111/J.1365-2141.2009.07606.X

Identifiers

DOI

1 reference

13 August 2017

1 reference

13 August 2017

PubMed publication ID

19236377

1 reference